An Open-Label, Single-Dose Study of the Mass Balance and Metabolic Disposition of Orally Administered [14C]-Labeled HKI-272 in Healthy Male Subjects.
Phase of Trial: Phase I
Latest Information Update: 11 May 2012
At a glance
- Drugs Neratinib (Primary)
- Indications Breast cancer; Solid tumours
- Focus Pharmacokinetics
- Sponsors Wyeth
- 11 May 2012 Company added as trial sponsor and additional lead trial centre identified as reported by ClinicalTrials.gov.
- 11 May 2012 Actual initiation date changed from Apr 2008 to Mar 2008 as reported by ClinicalTrials.gov.
- 01 May 2009 Actual end date (Apr 2008) added as reported by ClinicalTrials.gov.